Jci_page_head_homepage_01 Jci_page_head_homepage_02
Sean Maloney, Anajane Smith, Daniel E. Furst, David Myerson, Kate Rupert, Paul C. Evans, J. Lee Nelson
Published in Volume 104, Issue 1
J Clin Invest. 1999; 104(1):41–47 doi:10.1172/JCI6611
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

HLA-DRB5*01-specific PCR of DNA extracted from PBMCs of a scleroderma patient and a normal subject. The DRB5 gene is present only on some HLA haplotypes. Both mothers had DRB5*01 and both subjects did not. Lanes 3 and 4 are patient samples (different aliquots from the same draw date). Negative controls from homozygous cell lines with alleles similar to the patient’s are shown in lanes 5 and 6, and a positive homozygous control is shown in lane 7. Lanes 8–11 are 2 draw dates from a normal subject. Lanes 12 and 13 are negative cell line controls, and lane 14 is a positive homozygous cell line control. Lane 2 is blank. There was no alternative source of DRB5*01 DNA in the normal subject. The scleroderma patient also had children with DRB5*01 (see text).